Keros Therapeutics, Inc. (KROS)
NASDAQ: KROS · Real-Time Price · USD
10.58
-0.52 (-4.68%)
Aug 20, 2026, 10:05 AM EDT - Market open
Keros Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 257.61 | 287.42 | 559.93 | 331.15 | 279.05 | 230.04 |
Cash & Short-Term Investments | 257.61 | 287.42 | 559.93 | 331.15 | 279.05 | 230.04 |
Cash Growth | -62.68% | -48.67% | 69.09% | 18.67% | 21.30% | -13.48% |
Accounts Receivable | - | 3.57 | 2.74 | 0.14 | - | 18 |
Other Receivables | 3.3 | 17.29 | 1.71 | 0.95 | 0.84 | 0.2 |
Receivables | 3.3 | 20.85 | 4.46 | 1.09 | 0.84 | 18.2 |
Prepaid Expenses | 2.31 | 2.76 | 1.76 | 1.64 | 2.28 | 1.38 |
Other Current Assets | 3.66 | 4.4 | 22.74 | 13.42 | 3.6 | 1.82 |
Total Current Assets | 266.88 | 315.43 | 588.89 | 347.29 | 285.77 | 251.44 |
Property, Plant & Equipment | 19.27 | 21.14 | 23.49 | 19.47 | 17.57 | 2.4 |
Other Long-Term Assets | 1.45 | 1.45 | 3.51 | 3.26 | 3.45 | 1.41 |
Total Assets | 287.6 | 338.02 | 615.89 | 370.03 | 306.78 | 255.25 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 1.82 | 1.97 | 4.6 | 5.45 | 3.34 | 3.65 |
Accrued Expenses | 7.2 | 12.45 | 20.45 | 17.25 | 12 | 7.03 |
Current Portion of Leases | 2.6 | 2.41 | 1.98 | 1.01 | 0.46 | 0.86 |
Current Income Taxes Payable | 0.06 | 3.38 | - | - | - | 0.11 |
Other Current Liabilities | 0.48 | 0.22 | 0.42 | 0.67 | 0.75 | 0.2 |
Total Current Liabilities | 12.15 | 20.41 | 27.45 | 24.37 | 16.55 | 11.85 |
Long-Term Leases | 13.13 | 14.48 | 16.88 | 13.44 | 12.81 | 0.23 |
Total Liabilities | 25.28 | 34.89 | 44.33 | 37.81 | 29.36 | 12.08 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 1,181 | 1,169 | 1,140 | 713.64 | 505.86 | 366.93 |
Retained Earnings | -534.18 | -481.77 | -568.78 | -381.43 | -228.43 | -123.76 |
Treasury Stock | -384.56 | -384.56 | - | - | - | - |
Total Common Equity | 262.32 | 303.13 | 571.55 | 332.21 | 277.42 | 243.17 |
Shareholders' Equity | 262.32 | 303.13 | 571.55 | 332.21 | 277.42 | 243.17 |
Total Liabilities & Equity | 287.6 | 338.02 | 615.89 | 370.03 | 306.78 | 255.25 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 15.72 | 16.88 | 18.86 | 14.44 | 13.27 | 1.09 |
Net Cash (Debt) | 241.88 | 270.53 | 541.07 | 316.7 | 265.78 | 228.95 |
Net Cash Growth | -64.02% | -50.00% | 70.84% | 19.16% | 16.09% | -13.60% |
Net Cash Per Share | 9.03 | 7.15 | 14.45 | 10.75 | 10.53 | 9.81 |
Filing Date Shares Outstanding | 19.83 | 19.72 | 40.56 | 35.98 | 28.54 | 24 |
Total Common Shares Outstanding | 19.83 | 19.54 | 40.55 | 31.84 | 27.54 | 23.97 |
Working Capital | 254.73 | 295.02 | 561.44 | 322.92 | 269.22 | 239.59 |
Book Value Per Share | 13.23 | 15.51 | 14.09 | 10.43 | 10.07 | 10.14 |
Tangible Book Value | 262.32 | 303.13 | 571.55 | 332.21 | 277.42 | 243.17 |
Tangible Book Value Per Share | 13.23 | 15.51 | 14.09 | 10.43 | 10.07 | 10.14 |
Machinery | - | 8.73 | 7.19 | 5.85 | 2.97 | 1.92 |
Leasehold Improvements | - | - | - | - | 0.21 | 0.26 |